RxDoctor Payments Data

Jaipal Sidhu, MD

Pain Medicine · Fresno, CANPI 1689752305

Payments from drug & device makers

$3,562in general payments, 2019–2025

Across 244 payments — averaging $14.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Teva Pharmaceuticals USA, Inc.$835
  • Biodelivery Sciences International, Inc.$579
  • GRT US Holding, Inc.$140
  • Scilex Pharmaceuticals Inc.$126
  • Lilly USA, LLC$121
  • plus $519 from 15 others

What the payments were for

  • Food & beverage$3,562100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,562 in reported general payments places this provider in the 60th percentile of 840 pain medicine providers in California.

See all pain medicine providers in California

Medicare billing

Part B allowed, 2024
$253,015
Medicare patients
115
Services billed
3,681

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl105$85,140
RelistorMethylnaltrexone Bromide33$82,628
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,298$21,259
Xtampza ErOxycodone Myristate26$14,047
Buprenorphine72$14,040
Morphine Sulfate ErMorphine Sulfate324$10,360
NucyntaTapentadol Hcl15$8,880
Hysingla ErHydrocodone Bitartrate13$8,772
Tizanidine Hcl549$6,852
Gabapentin370$5,341
Oxymorphone Hcl ErOxymorphone Hcl18$5,276
Pregabalin119$4,943
Celecoxib129$4,292
Diclofenac Sodium168$3,461
Sulindac259$3,148

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$1,242$82,62833 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 840 pain medicine providers in California.

Other pain medicine in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →